<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934204</url>
  </required_header>
  <id_info>
    <org_study_id>GDREC2015431H(R1)</org_study_id>
    <nct_id>NCT02934204</nct_id>
  </id_info>
  <brief_title>Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma</brief_title>
  <official_title>Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Consolidation treatment for Primary Central Nervous System Diffuse Large B cell
      Lymphoma(PCNSL)patients remains to be defined.Here we designed a tolerated treatment of HDMTX
      plus Temozolomide,followed by consolidation with Temozolomide in PCNSL patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event free survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic neurotoxicity</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completed response</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Primary CNS Lymphoma</condition>
  <arm_group>
    <arm_group_label>MTX and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy:
Methotrexate 3.5g/m2 ivgtt d1 2weeks/cycleï¼Œtotal 8 cycles Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 4 cycles
Consolidation therapy:
PCNSL patients achieve CR,Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 12 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>MTX and Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>MTX and Temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - (1) histology confirmed to be PCNSL. (2) lymphoma invasion in brain, meninges,
        cerebrospinal fluid, eye organ. (3) ECOG score less than 3 points (4) at least 1 of the
        lesions can be evaluated with a double diameter. (5) the life expectancy of more than 6
        months. (6) less or equal to 75 years,or more or equal to 18 years. (7) to be able to
        comply with the requirements of the study and follow-up procedures.

        (8) to sign the consent form to participate in the study. (9) having adequate organ
        function, defined as follows: Liver function, serum aspartate aminotransferase (AST) and
        serum alanine aminotransferase (ALT) equal to or less than 2 times the upper limit of
        normal (ULN).

        Bone marrow function: absolute neutrophil count more or equal to 1500/L, platelet count
        more than 100000/L,hemoglobin was greater than 9 g/dL.

        Renal function, serum creatinine or creatinine clearance rate (less than 1.5ULN
        Cockcroft-Gault formula based on the improvement of more than 50ml/min).

        (10) women with childbearing potential must start to get the test results of serum / urine
        pregnancy test negative within 48 hours prior to study. Postmenopausal women who have at
        least 12 months of menopause can be treated as non fertile.

        Exclusion Criteria:

          -  (1) patients with a history of other malignancies within five years (except for the
             full treatment of cervical carcinoma in situ or basal cell carcinoma or squamous cell
             skin cancer).

             (2) had previously been treated with total cranial irradiation. (3) the upper
             digestive tract is lack of physical integrity, or suffering from malabsorption
             syndrome, or oral drug, or active gastric ulcer.

             (4) suffering from any unstable systemic diseases (including active infection,
             significant cardiovascular disease, any significant liver and kidney or metabolic
             disorders), metabolic disorders, physical examination results or laboratory
             examination results of contraindication to the use of drugs, or may affect the
             treatment results of interpretation or increase the risk of complications in treatment
             of risk (5) patients with human immunodeficiency virus (HIV) transmitted in the form
             of blood or other body fluids.

             (6) women in pregnancy and lactation. (7) women of childbearing age who do not want to
             use contraceptive measures during the study period and have sexual capacity of men.

             (8) patients who do not want to sign informed consent. (9) patients who were not
             willing to follow up. (10) for any drugs or excipients of allergy. Exit the case: no
             matter what reason patients withdrew from the study of cases in time will be
             postponed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenyu Li, MD PhD</last_name>
    <phone>+86 20 81884713</phone>
    <phone_ext>80411</phone_ext>
    <email>LiWY1206@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sichu Liu, MD PhD</last_name>
    <phone>+86 20 81884713</phone>
    <phone_ext>80411</phone_ext>
    <email>sisi.lau@foxmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong general hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sichu Liu, MD PhD</last_name>
      <phone>+86 20 81884713</phone>
      <phone_ext>80411</phone_ext>
      <email>sisi.lau@foxmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCNSL</keyword>
  <keyword>DLBCL</keyword>
  <keyword>methotrexate</keyword>
  <keyword>temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

